Bpth full form

12.42M Revenue (ttm) n/a Net Income (ttm) -15.78M Shares Out 7.96M EPS (ttm) -2.10 PE Ratio n/a Forward PE n/a Dividend n/a Ex-Dividend Date n/a Volume 27,664 Open 1.57 Previous Close 1.65 Day's Range 1.51 - 1.67 52-Week Range 1.18 - 4.48 Beta 1.31 Analysts n/a Price Target n/a Earnings Date Aug 15, 2023 About BPTH Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing...

• Markets • Stocks • Funds • ETFs • Bonds • Investing Ideas • Best Investments • Christine Benz’s Portfolios • Best Companies to Own • Best ETFs • Guide to 529 Plans • Asset Management Companies • Topics • Portfolio Construction • Economy • Sustainable Investing • Personal Finance • Retirement • Save for College • Start Investing • For Advisors • Alternative Investments • Media • Podcasts • Free Email Newsletters • Morningstar Magazine • Videos • Investing Definitions • Just For Investors • Morningstar Investor • Morningstar Investor Newsletters • Legacy Portfolio Manager Morningstar Quantitative ratings for equities (denoted on this page by ) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Business Description Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low...

• 7:48p Barron's An Important Stock Market Milestone Sets the Stage for More Gains • 7:36p Barron's A Schwab Wealth Survey Reveals a Paradox • 7:33p Barron's Look Out, Nvidia: Kroger Is an AI Stock Now • 7:27p These money and investing tips can get your stock and bond portfolio into shape • 6:54p Barron's The Fed Doesn’t Like Dissent. That Could Be a Problem. • 6:50p Barron's Adidas Stock’s Comeback Plan: China, Messi, and No More Yeezy • 6:48p Bank lending falls for first time in a month, Fed says • 6:40p Barron's Alkermes, Cogent Biosciences See Activist Action • 6:37p MedMen CFO Bowman resigns • 6:35p Barron's Netflix Stock Can Hit $500 • • to be replaced Key Data • Open $1.5700 • Day Range 1.5100 - 1.6699 • 52 Week Range 1.1750 - 4.4783 • Market Cap $13.13M • Shares Outstanding 7.96M • Public Float 7.93M • Beta 0.63 • Rev. per Employee N/A • P/E Ratio N/A • EPS -$2.1302 • Yield N/A • Dividend N/A • Ex-Dividend Date N/A • Short Interest 80.3K 05/31/23 • % of Float Shorted 1.01% • Average Volume 25.59K Bio-Path Holdings Inc. Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

• Markets • Stocks • Funds • ETFs • Bonds • Investing Ideas • Best Investments • Christine Benz’s Portfolios • Best Companies to Own • Best ETFs • Guide to 529 Plans • Asset Management Companies • Topics • Portfolio Construction • Economy • Sustainable Investing • Personal Finance • Retirement • Save for College • Start Investing • For Advisors • Alternative Investments • Media • Podcasts • Free Email Newsletters • Morningstar Magazine • Videos • Investing Definitions • Just For Investors • Morningstar Investor • Morningstar Investor Newsletters • Legacy Portfolio Manager Morningstar Quantitative ratings for equities (denoted on this page by ) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Business Description Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low...

• 7:48p Barron's An Important Stock Market Milestone Sets the Stage for More Gains • 7:36p Barron's A Schwab Wealth Survey Reveals a Paradox • 7:33p Barron's Look Out, Nvidia: Kroger Is an AI Stock Now • 7:27p These money and investing tips can get your stock and bond portfolio into shape • 6:54p Barron's The Fed Doesn’t Like Dissent. That Could Be a Problem. • 6:50p Barron's Adidas Stock’s Comeback Plan: China, Messi, and No More Yeezy • 6:48p Bank lending falls for first time in a month, Fed says • 6:40p Barron's Alkermes, Cogent Biosciences See Activist Action • 6:37p MedMen CFO Bowman resigns • 6:35p Barron's Netflix Stock Can Hit $500 • • to be replaced Key Data • Open $1.5700 • Day Range 1.5100 - 1.6699 • 52 Week Range 1.1750 - 4.4783 • Market Cap $13.13M • Shares Outstanding 7.96M • Public Float 7.93M • Beta 0.63 • Rev. per Employee N/A • P/E Ratio N/A • EPS -$2.1302 • Yield N/A • Dividend N/A • Ex-Dividend Date N/A • Short Interest 80.3K 05/31/23 • % of Float Shorted 1.01% • Average Volume 25.59K Bio-Path Holdings Inc. Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Klicken Sie auf „ Alle akzeptieren“, verwenden wir und • personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen • die Effektivität von personalisierten Anzeigen und Inhalten zu messen, sowie • unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern Klicken Sie auf „ Alle ablehnen“, wenn Sie nicht möchten, dass wir und unsere Partner Cookies und personenbezogene Daten für diese zusätzlichen Zwecke verwenden. Wenn Sie Ihre Auswahl anpassen möchten, klicken Sie auf „ Datenschutzeinstellungen verwalten“. Sie können Ihre Einstellungen jederzeit ändern, indem Sie auf unseren Websites und Apps auf den Link „Datenschutz- und Cookie-Einstellungen“ oder „Datenschutz-Dashboard“ klicken. Weitere Informationen darüber, wie wir Ihre personenbezogenen Daten nutzen, finden Sie in unserer